-, RIVAROXABAN, RIVAROXABAN
APHP220673
Phase 2 small_molecule active
Quick answer
-, RIVAROXABAN, RIVAROXABAN for newly diagnosed or relapsing deep venous thrombosis related to Behçet’s syndrome is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- newly diagnosed or relapsing deep venous thrombosis related to Behçet’s syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active